{"id":"androgen-receptor","name":"Androgen receptor","symbol":"AR","route":"/targets/androgen-receptor/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:644","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169083","uniprot":"https://www.uniprot.org/uniprotkb/P10275/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P10275","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1871","open-targets":"https://platform.opentargets.org/target/ENSG00000169083","civic":"https://civicdb.org/genes/367/summary","oncokb":"https://www.oncokb.org/gene/AR","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AR","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=AR","depmap":"https://depmap.org/portal/gene/AR?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000169083-AR","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/367","omim":"https://www.omim.org/entry/313700"}],"products":[{"id":"abiraterone","name":"Abiraterone acetate","status":"approved","modality":"Small-molecule CYP17A1 inhibitor","route":"/drugs/abiraterone/"},{"id":"apalutamide","name":"Apalutamide","status":"approved","modality":"Small-molecule AR antagonist","route":"/drugs/apalutamide/"},{"id":"azd9750","name":"AZD9750","status":"phase-2","modality":"protein degrader","route":"/drugs/azd9750/"},{"id":"bicalutamide","name":"Bicalutamide","status":"approved","modality":"Oral first-generation non-steroidal antiandrogen","route":"/drugs/bicalutamide/"},{"id":"bms-986365","name":"BMS-986365","status":"phase-3","modality":"protein degrader","route":"/drugs/bms-986365/"},{"id":"darolutamide","name":"Darolutamide","status":"approved","modality":"Small-molecule AR antagonist","route":"/drugs/darolutamide/"},{"id":"degarelix","name":"Degarelix","status":"approved","modality":"GnRH antagonist depot","route":"/drugs/degarelix/"},{"id":"enzalutamide","name":"Enzalutamide","status":"approved","modality":"Small-molecule AR antagonist","route":"/drugs/enzalutamide/"},{"id":"ep0062","name":"EP0062","status":"phase-2","modality":"small molecule","route":"/drugs/ep0062/"},{"id":"fluoxymesterone","name":"Fluoxymesterone","status":"historic","modality":"Oral small-molecule synthetic androgen","route":"/drugs/fluoxymesterone/"},{"id":"flutamide","name":"Flutamide","status":"approved","modality":"Non-steroidal antiandrogen (first generation)","route":"/drugs/flutamide/"},{"id":"galeterone","name":"Galeterone","status":"withdrawn","modality":"small molecule","route":"/drugs/galeterone/"},{"id":"leuprolide","name":"Leuprolide (leuprorelin) and GnRH agonists","status":"approved","modality":"GnRH agonist depot","route":"/drugs/leuprolide/"},{"id":"masofaniten","name":"Masofaniten","status":"withdrawn","modality":"Small-molecule AR N-terminal domain inhibitor","route":"/drugs/masofaniten/"},{"id":"mevrometostat","name":"Mevrometostat","status":"phase-3","modality":"Small-molecule EZH2 inhibitor","route":"/drugs/mevrometostat/"},{"id":"nilutamide","name":"Nilutamide","status":"approved","modality":"Non-steroidal antiandrogen (first generation)","route":"/drugs/nilutamide/"},{"id":"qlh12016","name":"QLH12016","status":"phase-2","modality":"protein degrader","route":"/drugs/qlh12016/"},{"id":"rezvilutamide","name":"Rezvilutamide","status":"approved","modality":"Oral androgen receptor antagonist","route":"/drugs/rezvilutamide/"},{"id":"triptorelin","name":"Triptorelin","status":"approved","modality":"GnRH agonist depot","route":"/drugs/triptorelin/"}],"trials":[{"id":"nct04497844","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","nct":"NCT04497844","phase":"3","status":"active"},{"id":"peace-3","name":"PEACE-3 (EORTC 1333)","nct":"NCT02194842","phase":"3","status":"positive"},{"id":"capitello-281","name":"CAPItello-281","nct":"NCT04493853","phase":"3","status":"positive"},{"id":"keynote-641","name":"KEYNOTE-641","nct":"NCT03834493","phase":"3","status":"negative"},{"id":"keynote-991","name":"KEYNOTE-991","nct":"NCT04191096","phase":"3","status":"negative"},{"id":"nct04446117","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","nct":"NCT04446117","phase":"3","status":"active"},{"id":"nct05171816","name":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","nct":"NCT05171816","phase":"3","status":"active"},{"id":"aranote","name":"ARANOTE","nct":"NCT04736199","phase":"3","status":"positive"},{"id":"radicals-hd","name":"RADICALS-HD","nct":"ISRCTN40814031","phase":"3","status":"positive"},{"id":"nct04076059","name":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo","nct":"NCT04076059","phase":"3","status":"active"},{"id":"embark","name":"EMBARK","nct":"NCT02319837","phase":"3","status":"positive"},{"id":"talapro-2","name":"TALAPRO-2","nct":"NCT03395197","phase":"3","status":"positive"},{"id":"nct01517802","name":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","nct":"NCT01517802","phase":"3","status":"completed"},{"id":"nct02663908","name":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","nct":"NCT02663908","phase":"3"},{"id":"arasens","name":"ARASENS","nct":"NCT02799602","phase":"3","status":"positive"},{"id":"imbassador250","name":"IMbassador250","nct":"NCT03016312","phase":"3","status":"negative"},{"id":"magnitude","name":"MAGNITUDE","nct":"NCT03748641","phase":"3","status":"mixed"},{"id":"propel","name":"PROpel","nct":"NCT03732820","phase":"3","status":"positive"},{"id":"nct00567580","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","nct":"NCT00567580","phase":"3","status":"positive"},{"id":"nct00936390","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","nct":"NCT00936390","phase":"3","status":"completed"},{"id":"nct02257736","name":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","nct":"NCT02257736","phase":"3","status":"active"},{"id":"peace-1","name":"PEACE-1","nct":"NCT01957436","phase":"3","status":"positive"},{"id":"getug-afu-17","name":"GETUG-AFU 17","nct":"NCT00667069","phase":"3","status":"mixed"},{"id":"hero","name":"HERO","nct":"NCT03085095","phase":"3","status":"positive"},{"id":"nct02489318","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","nct":"NCT02489318","phase":"3","status":"active"},{"id":"aramis","name":"ARAMIS","nct":"NCT02200614","phase":"3","status":"positive"},{"id":"arches","name":"ARCHES","nct":"NCT02677896","phase":"3","status":"positive"},{"id":"armor3-sv","name":"ARMOR3-SV","nct":"NCT02438007","phase":"3","status":"negative"},{"id":"card","name":"CARD","nct":"NCT02485691","phase":"3","status":"positive"},{"id":"enzamet","name":"ENZAMET","nct":"NCT02446405","phase":"3","status":"positive"},{"id":"era-223","name":"ERA 223","nct":"NCT02043678","phase":"3","status":"negative"},{"id":"nct01946204","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","nct":"NCT01946204","phase":"3","status":"active"},{"id":"prosper","name":"PROSPER","nct":"NCT02003924","phase":"3","status":"positive"},{"id":"latitude","name":"LATITUDE","nct":"NCT01715285","phase":"3","status":"positive"},{"id":"rtog-9601","name":"RTOG 9601","nct":"NCT00002874","phase":"3","status":"positive"},{"id":"nct00066703","name":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","nct":"NCT00066703","phase":"3","status":"completed"},{"id":"dart-01-05-gicor","name":"DART 01/05 GICOR","nct":"NCT02175212","phase":"3","status":"positive"},{"id":"nct00004054","name":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","nct":"NCT00004054","phase":"3","status":"completed"},{"id":"nct00002633","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","nct":"NCT00002633","phase":"3","status":"completed"},{"id":"prevail","name":"PREVAIL","nct":"NCT01212991","phase":"3","status":"positive"},{"id":"cou-aa-302","name":"COU-AA-302","nct":"NCT00887198","phase":"3","status":"positive"},{"id":"affirm","name":"AFFIRM","nct":"NCT00974311","phase":"3","status":"positive"},{"id":"nct00884273","name":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","nct":"NCT00884273","phase":"3","status":"completed"},{"id":"nct00833248","name":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","nct":"NCT00833248","phase":"3","status":"completed"},{"id":"cou-aa-301","name":"COU-AA-301","nct":"NCT00638690","phase":"3","status":"positive"},{"id":"spcg-7","name":"SPCG-7/SFUO-3","nct":"ISRCTN01534787","phase":"3","status":"positive"},{"id":"rtog-9202","name":"RTOG 92-02","phase":"3","status":"mixed"},{"id":"nct04691804","name":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver","nct":"NCT04691804","phase":"3","status":"active"},{"id":"nct07241416","name":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","nct":"NCT07241416","phase":"3","status":"recruiting"},{"id":"nct04557059","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","nct":"NCT04557059","phase":"3","status":"active"},{"id":"nct05884398","name":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","nct":"NCT05884398","phase":"3","status":"active"},{"id":"nct03767244","name":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","nct":"NCT03767244","phase":"3","status":"active"},{"id":"nct07213674","name":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ","nct":"NCT07213674","phase":"3","status":"recruiting"},{"id":"nct05794906","name":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer","nct":"NCT05794906","phase":"3","status":"active"},{"id":"nct06764485","name":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","nct":"NCT06764485","phase":"3","status":"active"},{"id":"nct06629779","name":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","nct":"NCT06629779","phase":"3","status":"recruiting"},{"id":"nct02531516","name":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","nct":"NCT02531516","phase":"3","status":"active"},{"id":"nct05112965","name":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","nct":"NCT05112965","phase":"3","status":"active"},{"id":"nct07611110","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","nct":"NCT07611110","phase":"3","status":"recruiting"},{"id":"nct03777982","name":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","nct":"NCT03777982","phase":"3"},{"id":"nct01020448","name":"Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","nct":"NCT01020448","phase":"3","status":"completed"},{"id":"nct00002881","name":"Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer","nct":"NCT00002881","phase":"3","status":"completed"},{"id":"nct00412022","name":"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer","nct":"NCT00412022","phase":"3"},{"id":"nct00003653","name":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","nct":"NCT00003653","phase":"3","status":"completed"},{"id":"nct00055731","name":"Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse","nct":"NCT00055731","phase":"3","status":"completed"},{"id":"nct07620574","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","nct":"NCT07620574","phase":"3","status":"recruiting"},{"id":"mevpro-1","name":"MEVPRO-1","nct":"NCT06551324","phase":"3","status":"active"},{"id":"nct04906395","name":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","nct":"NCT04906395","phase":"3","status":"active"},{"id":"nct03678025","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","nct":"NCT03678025","phase":"3","status":"recruiting"},{"id":"nct04821622","name":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","nct":"NCT04821622","phase":"3","status":"active"},{"id":"nct04464226","name":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","nct":"NCT04464226","phase":"3","status":"active"},{"id":"nct06520345","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","nct":"NCT06520345","phase":"3","status":"recruiting"},{"id":"nct07028853","name":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En","nct":"NCT07028853","phase":"3","status":"recruiting"},{"id":"nct04423211","name":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","nct":"NCT04423211","phase":"3","status":"recruiting"},{"id":"nct00104741","name":"Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer","nct":"NCT00104741","phase":"3","status":"completed"},{"id":"nct04513717","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","nct":"NCT04513717","phase":"3","status":"active"},{"id":"nct03706365","name":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","nct":"NCT03706365","phase":"2/3","status":"active"},{"id":"nct03348670","name":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","nct":"NCT03348670","phase":"2/3","status":"active"},{"id":"stampede","name":"STAMPEDE","nct":"NCT00268476","phase":"platform","status":"positive"},{"id":"nct03431350","name":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","nct":"NCT03431350","phase":"2","status":"active"},{"id":"nct04325828","name":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","nct":"NCT04325828","phase":"2","status":"active"},{"id":"nct07553988","name":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","nct":"NCT07553988","phase":"2","status":"active"},{"id":"nct07005154","name":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","nct":"NCT07005154","phase":"2","status":"recruiting"},{"id":"nct02960022","name":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","nct":"NCT02960022","phase":"2","status":"active"},{"id":"nct06099769","name":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","nct":"NCT06099769","phase":"2","status":"recruiting"},{"id":"nct07230106","name":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","nct":"NCT07230106","phase":"2","status":"recruiting"},{"id":"nct07450599","name":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi","nct":"NCT07450599","phase":"2","status":"recruiting"},{"id":"nct07287150","name":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","nct":"NCT07287150","phase":"2","status":"recruiting"},{"id":"nct05422911","name":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","nct":"NCT05422911","phase":"2","status":"recruiting"},{"id":"nct06991556","name":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc","nct":"NCT06991556","phase":"2","status":"active"},{"id":"nct07455903","name":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","nct":"NCT07455903","phase":"2","status":"recruiting"},{"id":"nct06365788","name":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer","nct":"NCT06365788","phase":"2","status":"recruiting"},{"id":"nct06312670","name":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","nct":"NCT06312670","phase":"2","status":"completed"},{"id":"nct02815033","name":"Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide","nct":"NCT02815033","phase":"2","status":"completed"},{"id":"nct07016399","name":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","nct":"NCT07016399","phase":"2","status":"recruiting"},{"id":"nct02814968","name":"PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide","nct":"NCT02814968","phase":"2","status":"completed"},{"id":"nct07745361","name":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","nct":"NCT07745361","phase":"2","status":"recruiting"},{"id":"nct06228053","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","nct":"NCT06228053","phase":"2","status":"recruiting"},{"id":"nct04557449","name":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","nct":"NCT04557449","phase":"2","status":"active"},{"id":"nct04986423","name":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer","nct":"NCT04986423","phase":"2","status":"recruiting"},{"id":"nct06863272","name":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","nct":"NCT06863272","phase":"1/2","status":"recruiting"},{"id":"nct07198633","name":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","nct":"NCT07198633","phase":"1/2","status":"recruiting"},{"id":"nct07407283","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","nct":"NCT07407283","phase":"1/2","status":"recruiting"},{"id":"nct05914116","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","nct":"NCT05914116","phase":"1/2","status":"recruiting"},{"id":"nct06785636","name":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC","nct":"NCT06785636","phase":"1/2","status":"recruiting"},{"id":"nct07226986","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","nct":"NCT07226986","phase":"1/2","status":"recruiting"},{"id":"nct05067140","name":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","nct":"NCT05067140","phase":"1/2","status":"active"},{"id":"nct06568094","name":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","nct":"NCT06568094","phase":"1/2","status":"recruiting"},{"id":"nct04104776","name":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","nct":"NCT04104776","phase":"1/2","status":"recruiting"},{"id":"nct07336446","name":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","nct":"NCT07336446","phase":"1/2","status":"recruiting"},{"id":"nct06190899","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","nct":"NCT06190899","phase":"1/2","status":"recruiting"},{"id":"nct05573126","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","nct":"NCT05573126","phase":"1/2","status":"recruiting"},{"id":"nct05367440","name":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","nct":"NCT05367440","phase":"1/2","status":"active"},{"id":"nct02861573","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","nct":"NCT02861573","phase":"1/2","status":"active"},{"id":"nct06702995","name":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","nct":"NCT06702995","phase":"1/2","status":"recruiting"},{"id":"nct07190300","name":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in ","nct":"NCT07190300","phase":"1/2","status":"recruiting"}],"pathways":["ar-signaling","lineage-plasticity-neuroendocrine","prostate-cancer-signalling","rna-splicing","transcription-addiction"],"companies":["abbvie","astellas","astrazeneca","bayer","bms","ellipses-pharma","essa-pharma","ferring","foresee-pharmaceuticals","ipsen","hengrui","johnson-johnson","merck","monte-rosa","oakwood-laboratories","oric-pharmaceuticals","pfizer","qilu-pharmaceutical","takeda","verity-pharma","veru","zydus"],"keyPapers":["paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022","paper-stopsack-prostate-genomes-by-race-ccr-2022","paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021","paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021","paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021","paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020","paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020","paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019","paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019","paper-labrecque-mcrpc-phenotypes-jci-2019","paper-prophecy-arv7-validation-jco-2019","paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018","paper-traina-enzalutamide-ar-tnbc-jco-2018","paper-quigley-structural-variation-mcrpc-cell-2018","paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018","paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018","paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","paper-ren-chinese-prostate-whole-genome-eur-urol-2018","paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017","paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017","paper-ku-rb1-trp53-lineage-plasticity-science-2017","paper-mu-sox2-lineage-plasticity-science-2017","paper-stampede-abiraterone-nejm-2017","paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016","paper-beltran-nepc-divergent-evolution-nat-med-2016","paper-lehmann-tnbctype-4-refinement-plos-one-2016","paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016","paper-burstein-tnbc-genomic-subtypes-ccr-2015","paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","paper-gundem-evolutionary-history-lethal-metastatic-prostate-nature-2015","paper-antonarakis-ar-v7-resistance-nejm-2014","paper-beer-prevail-enzalutamide-nejm-2014","paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014","paper-abiraterone-acetate-prostate-n-engl-j-med-2013","paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013","paper-scher-affirm-enzalutamide-nejm-2012","paper-grasso-mutational-landscape-lethal-crpc-nature-2012","paper-lehmann-tnbc-subtypes-jci-2011","paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011","paper-taylor-integrative-genomic-profiling-cancer-cell-2010","paper-attard-abiraterone-phase-1-cyp17-jco-2008","paper-tomlins-tmprss2-ets-fusion-science-2005","paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004","paper-protac-concept-sakamoto-pnas-2001","paper-visakorpi-androgen-receptor-amplification-nat-genet-1995","paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995","paper-huggins-hodges-castration-serum-phosphatases-prostate-1941"],"hotspots":[{"label":"T878A","position":878,"kind":"resistance","drugs":["enzalutamide","darolutamide","pluvicto"]},{"label":"F877L","position":877,"kind":"resistance","drugs":["darolutamide","pluvicto"]},{"label":"L702H","position":702,"kind":"resistance","drugs":["enzalutamide"]},{"label":"W742C / H875Y","position":742,"kind":"resistance","drugs":["enzalutamide","darolutamide"]},{"label":"AR-V7 (splice variant, no LBD)","position":640,"kind":"resistance","drugs":[]}],"openQuestions":[],"assays":[],"resistance":[{"class":"ar-pathway","mechanism":"AR amplification and ligand-binding-domain mutations","category":"on-target"},{"class":"ar-pathway","mechanism":"AR splice variants (AR-V7)","category":"on-target"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}